FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127678046> ?p ?o ?g. }

• W2127678046 endingPage "301" @default.
• W2127678046 startingPage "295" @default.
• W2127678046 abstract "We report the results of a recent trial in elderly acute lymphoblastic leukemia (ALL) patients (>60 years). Initial chemotherapy consisted of one 14-day course with single-dose idarubicin plus vin-cristine-prednisone-L-asparaginase. Idarubicin was preferred to other anthracyclines because of its shorter time to response. Sequential outpatient postremission therapy included single-dose idarubicin plus vincristine-cyclophosphamide-L-asparaginase pulses, cranial irradiation with intrathecal methotrexate-cytarabine, flexible weekly vincristine-cyclophosphamide alternating with cytarabine-teniposide, and two-year standard maintenance with mercaptopurine-methotrexate. Granulocyte colony-stimulating factor (G-CSF) was added to induction and early consolidation courses. Twenty-two patients mainly with high-risk features entered the study: median age was 64 years (60–73), 40% of cases were CD 10 B-lineage and T-lineage ALL, 38% of CD10+ B-lineage ALL carried a BCR-ABL rearrangement, while 23% coexpressed myeloid antigen, 86% had L2 morphology, 50% had a blast count greater than 10 × 109/1, 54% had hepato-splenomegaly and lymphadenopathy. The complete remission (CR) rate after induction therapy was 59%. A partial remission was obtained in two cases. There were four early deaths (18%) and three refractory ALL (14%). Median time to response was 21 days. With G-CSF, the median duration of absolute neutropenia was 10.5 days. Flexible postremission therapy was very well tolerated, causing no major toxicity. With a median follow-up of 2.6 years, 3 patients remain alive in first CR (23%), 2 of whom at 21.3 months and 39.6 months, respectively. Median survival of responders was 12 months compared to only 1.2 months for nonre-sponders (p < 0.001). This moderate-dose idarubicin-containing and G-CSF-supported regimen was associated with a high early remission rate in elderly ALL. Postremission therapy results were modest, though not appreciably different from the general experience in this patient population. Because further escalation of drug intensity appears unjustified, attempts to document and reverse drug resistance patterns and restore a dysregulated apoptosis must be considered." @default.
• W2127678046 created "2016-06-24" @default.
• W2127678046 creator A5001591385 @default.
• W2127678046 creator A5004450449 @default.
• W2127678046 creator A5005558035 @default.
• W2127678046 creator A5010698340 @default.
• W2127678046 creator A5013529815 @default.
• W2127678046 creator A5019219622 @default.
• W2127678046 creator A5029235354 @default.
• W2127678046 creator A5034123305 @default.
• W2127678046 creator A5042134519 @default.
• W2127678046 creator A5055401685 @default.
• W2127678046 creator A5069072959 @default.
• W2127678046 date "1996-01-01" @default.
• W2127678046 modified "2023-10-14" @default.
• W2127678046 title "Age-Adapted Moderate-Dose Induction and Flexible Outpatient Postremission Therapy for Elderly Patients with Acute Lymphoblastic Leukemia" @default.
• W2127678046 cites W176326824 @default.
• W2127678046 cites W1989937920 @default.
• W2127678046 cites W1990189905 @default.
• W2127678046 cites W1994131428 @default.
• W2127678046 cites W2007107048 @default.
• W2127678046 cites W2007370979 @default.
• W2127678046 cites W2010576366 @default.
• W2127678046 cites W2016336220 @default.
• W2127678046 cites W2019793347 @default.
• W2127678046 cites W2023528629 @default.
• W2127678046 cites W2077708288 @default.
• W2127678046 cites W2106464073 @default.
• W2127678046 cites W2122962750 @default.
• W2127678046 cites W2191423525 @default.
• W2127678046 cites W2258528303 @default.
• W2127678046 cites W2418553870 @default.
• W2127678046 cites W4231961829 @default.
• W2127678046 cites W4233705508 @default.
• W2127678046 cites W4246060417 @default.
• W2127678046 doi "https://doi.org/10.3109/10428199609051761" @default.
• W2127678046 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8819079" @default.
• W2127678046 hasPublicationYear "1996" @default.
• W2127678046 type Work @default.
• W2127678046 sameAs 2127678046 @default.
• W2127678046 citedByCount "41" @default.
• W2127678046 countsByYear W21276780462012 @default.
• W2127678046 countsByYear W21276780462013 @default.
• W2127678046 countsByYear W21276780462014 @default.
• W2127678046 countsByYear W21276780462016 @default.
• W2127678046 countsByYear W21276780462017 @default.
• W2127678046 countsByYear W21276780462018 @default.
• W2127678046 countsByYear W21276780462021 @default.
• W2127678046 countsByYear W21276780462022 @default.
• W2127678046 crossrefType "journal-article" @default.
• W2127678046 hasAuthorship W2127678046A5001591385 @default.
• W2127678046 hasAuthorship W2127678046A5004450449 @default.
• W2127678046 hasAuthorship W2127678046A5005558035 @default.
• W2127678046 hasAuthorship W2127678046A5010698340 @default.
• W2127678046 hasAuthorship W2127678046A5013529815 @default.
• W2127678046 hasAuthorship W2127678046A5019219622 @default.
• W2127678046 hasAuthorship W2127678046A5029235354 @default.
• W2127678046 hasAuthorship W2127678046A5034123305 @default.
• W2127678046 hasAuthorship W2127678046A5042134519 @default.
• W2127678046 hasAuthorship W2127678046A5055401685 @default.
• W2127678046 hasAuthorship W2127678046A5069072959 @default.
• W2127678046 hasConcept C126322002 @default.
• W2127678046 hasConcept C141071460 @default.
• W2127678046 hasConcept C2776611710 @default.
• W2127678046 hasConcept C2776694085 @default.
• W2127678046 hasConcept C2776755627 @default.
• W2127678046 hasConcept C2778041864 @default.
• W2127678046 hasConcept C2778119113 @default.
• W2127678046 hasConcept C2778707968 @default.
• W2127678046 hasConcept C2778720950 @default.
• W2127678046 hasConcept C2779117419 @default.
• W2127678046 hasConcept C2779429289 @default.
• W2127678046 hasConcept C2781059491 @default.
• W2127678046 hasConcept C71924100 @default.
• W2127678046 hasConcept C90924648 @default.
• W2127678046 hasConceptScore W2127678046C126322002 @default.
• W2127678046 hasConceptScore W2127678046C141071460 @default.
• W2127678046 hasConceptScore W2127678046C2776611710 @default.
• W2127678046 hasConceptScore W2127678046C2776694085 @default.
• W2127678046 hasConceptScore W2127678046C2776755627 @default.
• W2127678046 hasConceptScore W2127678046C2778041864 @default.
• W2127678046 hasConceptScore W2127678046C2778119113 @default.
• W2127678046 hasConceptScore W2127678046C2778707968 @default.
• W2127678046 hasConceptScore W2127678046C2778720950 @default.
• W2127678046 hasConceptScore W2127678046C2779117419 @default.
• W2127678046 hasConceptScore W2127678046C2779429289 @default.
• W2127678046 hasConceptScore W2127678046C2781059491 @default.
• W2127678046 hasConceptScore W2127678046C71924100 @default.
• W2127678046 hasConceptScore W2127678046C90924648 @default.
• W2127678046 hasIssue "3-4" @default.
• W2127678046 hasLocation W21276780461 @default.
• W2127678046 hasLocation W21276780462 @default.
• W2127678046 hasOpenAccess W2127678046 @default.
• W2127678046 hasPrimaryLocation W21276780461 @default.
• W2127678046 hasRelatedWork W1982921117 @default.
• W2127678046 hasRelatedWork W2007442696 @default.
• W2127678046 hasRelatedWork W2030243370 @default.
• W2127678046 hasRelatedWork W2063116093 @default.

• next